Mapping the Landscape: What We Know (and Don’t Know) About Reducing Cannabis Harms
A scoping review published in European Archives of Psychiatry and Clinical Neuroscience identifies and classifies harm reduction strategies for cannabis into a three-part typology of legal, socio-organisational, and health-related interventions, but explicitly does not and cannot assess which strategies are effective given the current state of evidence.
Why This Matters
Cannabis use prevalence continues to rise globally, and an increasing number of jurisdictions are considering or implementing some form of legalization or decriminalization. Clinicians, public health professionals, and policymakers urgently need a structured understanding of what harm reduction options exist. Yet cannabis harm reduction has historically received far less research attention than harm reduction for opioids, in part because of longstanding policy concerns about appearing to condone use. A formal cataloguing of what has been tried or proposed, even without effectiveness data, represents a necessary first step toward building the evidence base that clinical and policy decisions will eventually require.
Clinical Summary
Cannabis harm reduction encompasses a broad range of strategies, from regulatory frameworks and packaging requirements to peer-based programs, safer use messaging, and motivational interviewing. Despite growing interest, the evidence base for these interventions remains remarkably thin. This scoping review, published in European Archives of Psychiatry and Clinical Neuroscience, systematically searched Embase.com and supplementary databases for English-language literature published between 2011 and 2022 across Europe, the Americas, Australia, and New Zealand. The author employed narrative synthesis to derive a three-part typology organizing identified strategies into legal interventions such as regulatory frameworks and child-safety packaging, socio-organisational interventions including cannabis social clubs and drug-checking services, and health-related interventions spanning safer consumption guidance and digital therapeutic tools.
From approximately 744 records retrieved, only 35 documents met eligibility criteria, a strikingly small yield that reflects the fragmented and underdeveloped state of this literature. Grey literature, advocacy documents, and qualitative studies dominate the included corpus. Critically, the review performs no quality appraisal of included documents and makes no attempt to assess the effectiveness of any catalogued strategy. The author states explicitly that such assessment is not possible given the current research landscape and would require fundamentally different study designs. Before any of these strategies can be recommended with confidence, controlled effectiveness trials and rigorous implementation research are needed across diverse policy contexts.
Dr. Caplan’s Take
What this review does well is name the elephant in the room: we have a growing list of cannabis harm reduction strategies being deployed or discussed around the world, and almost no rigorous evidence telling us which ones actually reduce harm. That is an uncomfortable truth for clinicians whose patients ask whether cannabis social clubs, vaporization, or lower-potency products represent safer choices. An honest answer requires acknowledging that our current recommendations rest largely on mechanistic reasoning and analogy to other substances rather than on direct evidence of benefit.
In practice, when patients ask about reducing cannabis-related risks, I focus on what we can defensibly support: avoiding combustion where possible, being cautious with high-potency concentrates, not driving under the influence, and screening for patterns of use that suggest developing dependence. I frame these as prudent, biologically plausible strategies rather than proven interventions, because that is what the evidence currently allows. This review confirms that we need much better data before we can do more than that.
Clinical Perspective
This scoping review sits at the very beginning of the research arc for cannabis harm reduction. It confirms that the field has generated a variety of proposed interventions but challenges any assumption that these strategies rest on solid effectiveness evidence. The 35-document yield across an 11-year window, dominated by qualitative and observational designs, underscores how far the field must travel before clinicians can make evidence-grounded recommendations about specific harm reduction approaches. For now, the typology serves as a useful inventory for researchers designing future effectiveness trials and for policymakers mapping their options, but it should not be interpreted as a menu of validated interventions to offer patients.
From a safety standpoint, clinicians should be aware that some catalogued strategies, such as recommending vaporization over combustion or steering patients toward lower-potency products, carry their own uncertainties. Vaporizer safety depends heavily on device quality and the composition of the material being heated, and potency thresholds for harm have not been rigorously established. Drug interactions between cannabis and commonly prescribed medications, particularly those metabolized through cytochrome P450 pathways, remain relevant regardless of delivery method. The most actionable step clinicians can take now is to routinely screen for cannabis use patterns, counsel on known risks including impaired driving and adolescent neurodevelopmental concerns, and document these conversations as part of standard care.
Study at a Glance
- Study Type
- Scoping review with systematic search (described by the author as an “evidence review”)
- Population
- Cannabis users across general and clinical populations; no specific clinical cohort defined
- Intervention
- Cannabis harm reduction strategies broadly defined across legal, socio-organisational, and health-related domains
- Comparator
- Not applicable (descriptive typology, no effectiveness comparison)
- Primary Outcomes
- Classification of identified strategies into a three-part typology
- Sample Size
- 35 eligible documents from approximately 744 records screened
- Journal
- European Archives of Psychiatry and Clinical Neuroscience
- Year
- 2025
- DOI or PMID
- Published online ahead of print; consult journal for DOI
- Funding Source
- Not explicitly reported in available data
What Kind of Evidence Is This
This is a scoping review, a form of systematic literature review designed to map the breadth of a research area rather than synthesize effectiveness evidence. Scoping reviews occupy a position in the evidence hierarchy below systematic reviews with meta-analysis and below individual controlled trials, because they do not assess study quality or pool outcomes. The single most important inference constraint this design imposes is that no conclusion about whether any identified strategy actually reduces harm can be drawn from this work alone.
How This Fits With the Broader Literature
Previous systematic reviews have addressed discrete components of cannabis harm reduction, including the effects of legalization on use patterns, the impact of packaging regulations, and impaired driving interventions. However, none has attempted a comprehensive mapping of the full range of harm reduction strategies across domains. This scoping review fills that structural gap by providing the first cross-domain typology, extending the conceptual work done by Fischer and colleagues on lower-risk cannabis use guidelines and by Casajuana Kogel and collaborators on interventions for cannabis use reduction.
The finding that only 35 documents met inclusion criteria is itself an important data point, confirming what several commentators have noted: cannabis harm reduction research lags years behind equivalent work on alcohol and opioids. The dominance of grey literature and qualitative designs in the included corpus further supports the conclusion that this field remains in an early descriptive phase rather than an evaluative one.
Common Misreadings
The most likely overinterpretation of this review is treating its typology as a validated toolkit of effective harm reduction strategies. Because the review catalogues what has been proposed or implemented rather than what has been shown to work, readers may incorrectly assume that the inclusion of a strategy in the typology constitutes evidence of its benefit. It does not. The author is explicit on this point, noting that effectiveness assessment is not possible given the current state of research. A second common misreading would be to conclude that the small number of included documents means harm reduction for cannabis has been neglected; while the evidence base is thin, the restrictive inclusion criteria, including English-only and specific geographic limits, may have excluded relevant work.
Bottom Line
This scoping review provides a useful organizational framework for the diverse range of cannabis harm reduction strategies that have been proposed, piloted, or implemented across multiple jurisdictions. It does not and cannot tell us which of these strategies actually work. For clinicians, the practical implication is clear: counsel patients on biologically plausible risk reduction, screen routinely for problematic use patterns, and await the controlled effectiveness trials that this typology is designed to help generate.
References
- Scoping review on cannabis harm reduction strategies. European Archives of Psychiatry and Clinical Neuroscience, 2025. Published online ahead of print.
- Fischer B, Russell C, Sabioni P, et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017;107(8):e1-e12. DOI: 10.2105/AJPH.2017.303818
- Casajuana Kogel C, Lopez-Pelayo H, Balcells-Olivero MM, et al. Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones, 2018;30(2):140-151.
- Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology, 2005;8(1):19-32. DOI: 10.1080/1364557032000119616
Have thoughts on this? Share it:
